The problem with doing this is that Leronlimab has

The problem with doing this is that Leronlimab hasn’t even been tested preclinically in Parkinson’s. I get it, the “MOA” shows that it “could” work for Parkinson’s, but that’s a lot different than positive results in established Parkinson’s models. At the point contacting him would be pointless as CYDY doesn’t have preclinical data ok Parkinson’s or even a phase 2 protocol for treatment of the indication.